Dapagliflozin improves cardiovascular risk factors in Emirati patients with T2DM

BACKGROUND: Dapagliflozin is a sodium–glucose co transporter-2 inhibitor that proved efficacy in reduction of blood glucose level through extrusion of glucose in urine. It is used in treatment of type 2 diabetes mellitus (T2DM). It also has reported cardiovascular and renal benefits in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Nada, Aml Mohamed, Younan, Mariam Adel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970182/
https://www.ncbi.nlm.nih.gov/pubmed/33796252
http://dx.doi.org/10.1177/2042018821995364

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970182/
https://www.ncbi.nlm.nih.gov/pubmed/33796252
http://dx.doi.org/10.1177/2042018821995364

Ejemplares similares